Will Lewis, Insmed CEO, joins 'Fast Money' to talk Insmed's rare gene therapy development, demand, and quarterly results.

UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today ...

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...

Bharat Biotech expands into advanced biologics with Nucelion Therapeutics, a new CRDMO for cell and gene therapy ...

UniQure stock crashed Monday on "confusing" and "unexpected" feedback from the FDA for its Huntington's disease gene therapy.

Qure (QURE) shares drop after FDA questions AMT-130 data for Huntington’s disease, delaying BLA submission. Read more here.

New Product Shortage PLUS Endorsement fills a critical coverage gap for injury-related claims arising from product unavailability or delivery failures ...

Bharat Biotech launches Nucelion Therapeutics, a CRDMO focused on advanced cell and gene therapies for global life science innovators.

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now ...